Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Ganswindt, Ute ^a   Paulsen, Frank ^a   Corvin, Stefan ^a   Eichhorn, Kai ^a   Glocker, Stefan ^a   Hundt, Ilse ^a   Birkner, Mattias ^a   Alber, Markus ^a   Anastasiadis, Aristotelis ^a   Stenzl, Arnulf ^a   Bares, Roland ^a   Budach, Wilfried ^b   Bamberg, Michael ^a   Belka, Claus ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NANOCOLL TC 99M;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEASIBILITY STUDY; GASTROINTESTINAL TOXICITY; HIGH RISK POPULATION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LARGE INTESTINE; MALE; PATHOLOGICAL ANATOMY; PRESCRIPTION; PROSTATE CANCER; RADIATION DOSE; RECTUM; SCINTILLATION CAMERA; SEMINAL VESICLE; SENTINEL LYMPH NODE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMALL INTESTINE; TUMOR LOCALIZATION; TUMOR VOLUME; UROGENITAL TRACT DISEASE; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; LYMPH NODE; LYMPH NODE METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RADIOMETRY; RISK;

AGED; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RISK; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 26944462395     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-91     Document Type: Article

References (54)

1. Coen JJ, Zietman AL, Thakral H, Shipley WU: Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 2002, 20:3199-3205.
2. Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, Hunt MA: Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998, 41:501-510.
3. Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Schultheiss TE: Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am 1999, 5:152-158.
4. Hanks GE, Hanlon AL, Epstein B, Horwitz EM: Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 2002, 54:427-435.
5. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Ling CC, Fuks Z: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998, 41:491-500.
6. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA: High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001, 166:876-881.
7. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA: High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002, 53:1111-1116.
8. Symon Z, Griffith KA, McLaughlin PW, Sullivan M, Sandler HM: Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy. Int J Radiat Oncol Biol Phys 2003, 57:384-390.
9. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I: Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000, 18:3904-3911.
10. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I: Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
11. Valicenti R, Lu J, Pilepich M, Asbell S, Grignon D: Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol 2000, 18:2740-2746.
12. Pollack A, Smith LG, von Eschenbach AC: External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 2000, 48:507-512.
13. Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T: Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 2000, 46:823-832.
14. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL: Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003, 57:915-928.
15. Pinover WH, Hanlon AL, Horwitz EM, Hanks GE: Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer. Int J Radiat Oncol Biol Phys 2000, 47:649-654.
16. Kupelian PA, Buchsbaum JC, Reddy CA, Klein EA: Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10). Int J Radiat Oncol Biol Phys 2001, 50:621-625.
17. Fiveash JB, Hanks G, Roach M, Wang S, Vigneault E, McLaughlin PW, Sandler HM: 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review. Int J Radiat Oncol Biol Phys 2000, 47:335-342.
18. Hurwitz MD, Schnieder L, Manola J, Beard CJ, Kaplan ID, D'Amico AV: Lack of radiation dose response for patients with low-risk clinically localized prostate cancer: a retrospective analysis. Int J Radiat Oncol Biol Phys 2002, 53:1106-1110.
19. Jani AB, Hand CM, Pelizzari CA, Roeske JC, Krauz L, Vijayakumar S: Biological-effective versus conventional dose volume histograms correlated with late genitourinary and gastrointestinal toxicity after external beam radiotherapy for prostate cancer: a matched pair analysis. BMC Cancer 2003, 3:16.
20. Ganswindt U, Paulsen F, Anastasiadis AG, Stenzl A, Bamberg M, Belka C: 70 Gy or more: which dose for which prostate cancer? J Cancer Res Clin Oncol 2005.
21. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360:103-106.
22. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003, 21:3972-3978.
23. Roach M, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CRJ, Shipley WS: Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003, 21:1904-1911.
24. Wawroschek F, Wagner T, Hamm M, Weckermann D, Vogt H, Markl B, Gordijn R, Harzmann R: The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 2003, 43:132-6; discussion 137..
25. Wawroschek F, Vogt H, Wengenmair H, Weckermann D, Hamm M, Keil M, Graf G, Heidenreich P, Harzmann R: Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 2003, 70:303-310.
26. Weckermann D, Wawroschek F, Harzmann R: Is there a need for pelvic lymph node dissection in low risk prostate cancer patients prior to definitive local therapy? Eur Urol 2005, 47:45-50; discussion 50-1.
27. Heidenreich A, Varga Z, Von Knobloch R: Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002, 167:1681-1686.
28. Martinez-Monge R, Fernandes PS, Gupta N, Gahbauer R: Cross-sectional nodal atlas: a tool for the definition of clinical target volumes in three-dimensional radiation therapy planning. Radiology 1999, 211:815-828.
29. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001, 58:843-848.
30. Alber M, Nusslin F: Optimization of intensity modulated radiotherapy under constraints for static and dynamic MLC delivery. Phys Med Biol 2001, 46:3229-3239.
31. Adli M, Mayr NA, Kaiser HS, Skwarchuk MW, Meeks SL, Mardirossian G, Paulino AC, Montebello JF, Gaston RC, Sorosky JI, Buatti JM: Does prone positioning reduce small bowel dose in pelvic radiation with intensity-modulated radiotherapy for gynecologic cancer? Int J Radiat Oncol Biol Phys 2003, 57:230-238.
32. Aristizabal SA, Steinbronn D, Heusinkveld RS: External beam radiotherapy in cancer of the prostate. The University of Arizona experience. Radiother Oncol 1984, 1:309-315.
33. Asbell SO, Krall JM, Pilepich MV, Baerwald H, Sause WT, Hanks GE, Perez CA: Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 1988, 15:1307-1316.
34. Asbell SO, Martz KL, Shin KH, Sause WT, Doggett RL, Perez CA, Pilepich MV: Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 1998, 40:769-782.
35. Harisiadis L, Veenema RJ, Senyszyn JJ, Puchner PJ, Tretter P, Romas NA, Chang CH, Lattimer JK, Tannenbaum M: Carcinoma of the prostate: treatment with external radiotherapy. Cancer 1978, 41:2131-2142.
36. Hill DR, Crews QEJ, Walsh PC: Prostate carcinoma: radiation treatment of the primary and regional lymphatics. Cancer 1974, 34:156-160.
37. Neglia WJ, Hussey DH, Johnson DE: Megavoltage radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1977, 2:873-883.
38. Rosen E, Cassady JR, Connolly J, Chaffey JT: Radiotherapy for prostate carcinoma: the JCRT experience (1968-1978). II. Factors related to tumor control and complications. Int J Radiat Oncol Biol Phys 1985, 11:723-730.
39. Rounsaville MC, Green JP, Vaeth JM, Purdon RP, Heltzel MM: Prostatic carcinoma: limited field irradiation. Int J Radiat Oncol Biol Phys 1987, 13:1013-1020.
40. Zagars GK, von Eschenbach AC, Johnson DE, Oswald MJ: Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer 1987, 60:1489-1499.
41. Zagars GK, von Eschenbach AC, Johnson DE, Oswald MJ: The role of radiation therapy in stages A2 and B adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1988, 14:701-709.
42. Seaward SA, Weinberg V, Lewis P, Leigh B, Phillips TL, Roach M: Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 1998, 42:1055-1062.
43. Bagshaw MA, Cox RS, Ray GR: Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr 1988:47-60.
44. McGowan DG: The value of extended field radiation therapy in carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1981, 7:1333-1339.
45. Perez CA, Michalski J, Brown KC, Lockett MA: Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1996, 36:573-584.
46. Ploysongsang S, Aron BS, Shehata WM, Jazy FK, Scott RM, Ho PY, Morand TM: Comparison of whole pelvis versus small-field radiation therapy for carcinoma of prostate. Urology 1986, 27:10-16.
47. Rangala N, Cox JD, Byhardt RW, Wilson JF, Greenberg M, Lopes da Conceicao A: Local control and survival after external irradiation for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1982, 8:1909-1914.
48. Hauschild A, Rosien F, Lischner S: Surgical standards in the primary care of melanoma patients. Onkologie 2003, 26:218-222.
49. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P, Renne G, De Cicco C, De Lucia F, Gennari R: A randomized comparison of sentinelnode biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003, 349:546-553.
50. Balkissoon J, Rasgon BM, Schweitzer L: Lymphatic mapping for staging of head and neck cancer. Semin Oncol 2004, 31:382-393.
51. Corvin S, Eichhorn K, Wurm T, Sturm W, Bares R, Stenzl A: Radio-isotope guided laparoscopic pelvic lymph node dissection - a novel technique for prostate cancer staging. Eur Urol 2004, 3 Supp:140.
52. Nutting CM, Convery DJ, Cosgrove VP, Rowbottom C, Padhani AR, Webb S, Dearnaley DP: Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 2000, 48:649-656.
53. Adams EJ, Convery DJ, Cosgrove VP, McNair HA, Staffurth JN, Vaarkamp J, Nutting CM, Warrington AP, Webb S, Balyckyi J, Dearnaley DP: Clinical implementation of dynamic and step-and-shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvement. Radiother Oncol 2004, 70:1-10.
54. Mundt AJ, Lujan AE, Rotmensch J, Waggoner SE, Yamada SD, Fleming G, Roeske JC: Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002, 52:1330-1337.